During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow -1.14% to 12151. S&P -1.25% to 1249. Nasdaq -1.34% to 2590.
Treasurys: 30-year +1.21%. 10-yr +0.48%. 5-yr +0.04%.
Commodities: Crude -1.8% to $99.52. Gold -2.68% to $1552.70.
Currencies: Euro -1.02% vs. dollar. Yen +0.14%. Pound -1.38%
After Hours News:
Chesapeake Midstream Partners (CHKM) agrees to acquire Appalachia Midstream Services, the wholly owned subsidiary of Chesapeake Midstream Development that holds its Marcellus Shale midstream assets, for $865M.
Fushi Copperweld (FSIN) rises 10.3% AH, to $8.23, after a group of investors that includes co-CEO Li Fu lift their buyout offer for the company by $0.25/share, to $9.50/share. More than the increase in the buyout price, Fushi shares appear to be rallying on account of the new offer raising investor hopes that a deal will actually go through.
Leggett & Platt (LEG) expects a Q4, largely non-cash, pre-tax charge of approximately $36M due to restructuring-related activity including the closure of certain manufacturing facilities. The charge will impact after-tax earnings only, therefore FY11 EPS expectations have not changed from prior $1.15 - 1.20 guidance issued in October
Alexion Pharmaceuticals (ALXN) agrees to buy privately-held biotech firm Enobia for $1.08B in cash - with $610M paid up front and the rest after various regulatory and sales milestones are hit. Enobia is focused on therapies treating patients with ultra-rare, life-threatening genetic disorders. Shares -1.3% AH
Leggett & Platt (LEG) expects a Q4, largely non-cash, pre-tax charge of approximately $36M due to restructuring-related activity including the closure of certain manufacturing facilities. The charge will impact after-tax earnings only, therefore FY11 EPS expectations have not changed from prior $1.15 - 1.20 guidance issued in October
Alexion Pharmaceuticals (ALXN) agrees to buy privately-held biotech firm Enobia for $1.08B in cash - with $610M paid up front and the rest after various regulatory and sales milestones are hit. Enobia is focused on therapies treating patients with ultra-rare, life-threatening genetic disorders. Shares -1.3% AH
Chipmaker Exar (EXAR) drops 3.3% AH after warning it expects FQ3 revenue of $28M-$30M and a gross margin of 48%-50%, below prior guidance of $32M-$34M and 49%-51%
http://daytradingstock-blog.blogspot.com/
